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Abstract: OBJECTIVE: Positron emission tomography (PET) using 18F-fluordeoxyglucose (F-FDG) is
an established imaging modality for tumor staging in patients with non-small cell lung cancer (NSCLC).
There is a growing interest in using F-FDG PET for therapy response assessment in NSCLC which
relies on quantitative PET parameters such as standardized uptake values (SUV). Different reconstruc-
tion algorithms in PET may affect SUV. We sought to determine the variation of SUV in patients with
NSCLC when using ordered subset expectation maximization (OSEM) and block sequential regularized
expectation maximization (BSREM) in latest-generation digital PET/CT, including a subanalysis for ade-
nocarcinoma and squamous cell carcinoma. METHODS: A total of 58 patients (34 = adenocarcinoma,
24 = squamous cell carcinoma) that underwent a clinically indicated F-FDG PET/CT for staging were
reviewed. PET images were reconstructed with OSEM and BSREM reconstruction with noise penalty
strength ฀-levels of 350, 450, 600, 800 and 1200. Lung tumors maximum standardized uptake value (SUV)
were compared. RESULTS: Lung tumors SUV were significantly lower in adenocarcinomas compared to
squamous cell carcinomas in all reconstructions evaluated (all p < 0.01). Comparing BSREM to OSEM,
absolute SUV differences were highest in lower ฀-levels of BSREM with + 2.9 ± 1.6 in adenocarcinoma
and + 4.0 ± 2.9 in squamous cell carcinoma, (difference between histology; p-values > 0.05). There was
a statistically significant difference of the relative increase of SUV in adenocarcinoma (mean + 34.8%)
and squamous cell carcinoma (mean 23.4%), when using BSREM instead of OSEM (p < 0.05). CON-
CLUSIONS: In NSCLC the relative change of SUV when using BSREM instead of OSEM is significantly
higher in adenocarcinoma as compared to squamous cell carcinoma. ADVANCES IN KNOWLEDGE:
The impact of BSREM on SUV may vary in different histological subtypes of NSCLC. This highlights
the importance for careful standardisation of ฀-value used for serial F-FDG PET scans when following-up
NSCLC patients.
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InTroDucTIon
Non-small cell lung cancer (NSCLC) is the most common 
cause of mortality from cancer worldwide.1 In NSCLC, 
positron emission tomography (PET) using 18F-fludeox-
yglucose (18F-FDG) as radiotracer in combination with 
CT is the established imaging modality for whole-body 
staging.2 The high correlation between maximum stan-
dardized uptake values (SUVmax) of 
18F-FDG PET/CT with 
histopathological tumor regression on radiotherapy3 as well 
as neoadjuvant chemotherapy4 in NSCLC patients lead to 
an increasing use of 18F-FDG PET for treatment response 
assessment.5 However, response assessment with abso-
lute quantitative methods for 18F-FDG PET/CT requires 
a fundamental standardization and global consensus on 
imaging protocols and post-processing. Therefore, rela-
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objective: Positron emission tomography (PET) using 
18F-fludeoxyglucose (18F-FDG) is an established imaging 
modality for tumor staging in patients with non-small 
cell lung cancer (NSCLC). There is a growing interest 
in using 18F-FDG PET for therapy response assessment 
in NSCLC which relies on quantitative PET parameters 
such as standardized uptake values (SUV). Different 
reconstruction algorithms in PET may affect SUV. We 
sought to determine the variation of SUV in patients 
with NSCLC when using ordered subset expectation 
maximization (OSEM) and block sequential regularized 
expectation maximization (BSREM) in latest-generation 
digital PET/CT, including a subanalysis for adenocarci-
noma and squamous cell carcinoma.
Methods: A total of 58 patients (34 = adenocarci-
noma, 24 = squamous cell carcinoma) who underwent 
a clinically indicated 18F-FDG PET/CT for staging were 
reviewed. PET images were reconstructed with OSEM 
and BSREM reconstruction with noise penalty strength 
β-levels of 350, 450, 600, 800 and 1200. Lung tumors 
maximum standardized uptake value (SUVmax) were 
compared.
results: Lung tumors SUVmax were significantly lower 
in adenocarcinomas compared to squamous cell carci-
nomas in all reconstructions evaluated (all p < 0.01). 
Comparing BSREM to OSEM, absolute SUVmax differ-
ences were highest in lower β-levels of BSREM with + 
2.9 ± 1.6 in adenocarcinoma and + 4.0 ± 2.9 in squamous 
cell carcinoma (difference between histology; p-values 
> 0.05). There was a statistically significant difference 
of the relative increase of SUVmax in adenocarcinoma 
(mean + 34.8%) and squamous cell carcinoma (mean 
23.4%), when using BSREM350 instead of OSEMTOF (p < 
0.05).
conclusion: In NSCLC the relative change of SUV when 
using BSREM instead of OSEM is significantly higher 
in adenocarcinoma as compared to squamous cell 
carcinoma.
advances in knowledge: The impact of BSREM on SUV 
may vary in different histological subtypes of NSCLC. 
This highlights the importance for careful standardiza-
tion of β-value used for serial 18F-FDG PET scans when 
following-up NSCLC patients.
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rates of tumors.6,7 Still this relative assessment warrants careful 
standardization of 18F-FDG PET/CT protocol within each insti-
tution, especially if used in multicenter trials, as otherwise the 
inherent value of quantitative PET may be lost.8 Besides the 
recommended control of blood glucose levels, standardized 
uptake time (60 min, range 55–75 min) and 18F-FDG dosage 
(MBq/kg), also image reconstruction is listed as an important 
factor for standardizing PET acquisition in order to provide reli-
able and reproducible quantification.9
In current clinical routine, ordered subset expectation maximi-
zation (OSEM) reconstruction is the most widely used algorithm 
for clinical PET/CT as it provides better image quality than the 
formerly used filtered back projection method.10 However, it is 
known that regardless of the reconstruction method used, PET 
generally underestimates the true SUV as a measure of tumor 
glucose metabolism.11 However, previous studies reported that 
newly clinically available Bayesian penalized likelihood (BPL) 
reconstruction algorithms such as block sequential regularized 
expectation maximization (BSREM) may increase the accuracy 
of lesion quantitation compared to OSEM (i.e. lead to an increase 
of SUV of metabolic active lung lesions).12 Meanwhile, the varia-
tion of PET SUVs due to different reconstruction methods intro-
duces some uncertainties when used for response assessment in 
NSCLC. It is not understood, if such SUV inconsistencies among 
different reconstruction may be clinically relevant or not.
Accordingly, we sought to determine the absolute and relative 
variation of SUV comparing OSEM and BSREM on a latest-gen-
eration digital PET/CT in patients with NSCLC, including 
subanalyses for adenocarcinoma and squamous cell carcinoma.
MeThoDs anD MaTerIals
Patient selection
Patients undergoing a clinically indicated 18F-FDG PET/CT scan 
between March 2017 and July 2018 were retrospectively included 
if they met the following inclusion criteria: (a) patients NSCLC 
referred for initial staging, (b) histologically confirmed adeno-
carcinoma or squamous cell carcinoma, (c) written informed 
consent for the subsequent use of medical data. A part of the 
study group was shared in a previous publication on another 
purpose than the present study. The study was approved by the 
local ethics committee. The study was conducted in compliance 
with ICH-GCP-rules and the Declaration of Helsinki.
PET/CT acquisition
All patients underwent a PET/CT on a novel digital detector 
scanner (GE Discovery Molecular Insights—DMI PET/CT, GE 
Healthcare, Waukesha, WI). A body mass index (BMI) adapted 
18F-FDG dosage protocol was used, based on recommendations 
for this specific digital PET detector13: a dose of 1.5 MBq per 
kilogram body weight was injected for patients with a BMI of 
<20 kg m–2, 2 MBq per kilogram body weight for patients with a 
BMI of 20–24.5 kg/m2, and 3.1 MBq per kilogram body weight 
for patients with a BMI >24.5 kg/m–2, up to a maximum of 320 
MBq. The participants fasted for at least 4 h prior to the scan 
and blood glucose levels were <160 mg dl−1 at the time of 18F-
FDG injection. A CT scan was obtained from the vertex to the 
mid-thighs and used for attenuation correction as well as to 
help for anatomic localization of 18F-FDG uptake. The CT was 
performed with automated dose modulation (range 15–100 mA, 
120 kV). After the CT, a PET scan was acquired covering the 
same anatomical region. The PET acquisition time was 2.5 min 
per bed position, with 6–8 bed positions per patient (depending 
on patient size), with an overlap of 23%. For calibration of the 
PET scanner used in the present study daily quality control is 
performed with an annulus Ge-68 phantom while well counter 
calibration for absolute quantification is performed with an F-18 
filled phantom.
PET data reconstructions
After PET image acquisition, data sets were reconstructed with 
seven different reconstruction settings per patient, two recon-
structions were using OSEM with two iterations, 24 subsets and 
6.4 mm Gaussian filter (1) with time-of-flight (TOF) acquisition 
(OSEMTOF; VUE Point FX, GE Healthcare, Waukesha, WI), (2) 
with TOF and point spread function (PSF) modelling (OSEMPSF; 
VUE Point FX with SharpIR, GE Healthcare, Waukesha, WI). 
Five reconstructions used BSREM (Q.Clear, GE Healthcare, 
Waukesha, WI) with incremental β-values of (3) 350, (4) 450, (5) 
600, (6) 800, and (7) 1200. All data sets were reconstructed with a 
256 × 256 pixel matrix. The background for choosing this recon-
struction settings was as follows: OSEMTOF is frequently used in 
clinical multicenter studies for the purpose of interscanner and 
intersite harmonization. OSEMPSF represents the latest recon-
struction technique used on many PET/CT systems. BSREM, 
on the other hand, is a full convergence algorithm that reaches 
high convergence, which may become a clinical standard in the 
future, at least for digital scanners.
Quantitative imaging analysis
Quantitative analyses were performed by two readers (D.A.F. 
and M.M., 3 and 6 years of experience in chest imaging). The 
SUVmax of each primary lung tumor was recorded using a stan-
dard volume of interest (VOI) tool including the whole tumor 
volume. Thereby, the VOI was automatically propagated to cover 
the exact same volume in all the different reconstruction sets. 
The cases with discrepancy of lung tumor SUVmax between the 
two readers were noted and resolved in consensus.
Further, as a measure of image noise the standard deviation of the 
standardized uptake value (SUVSD) in the right lobe of the liver 
(parenchymal organ background) and within the descending 
aorta (bloodpool background) at the level of the carina was 
measured using a 4.0 cm and 1.0 cm diameter spherical VOI, 
respectively.
Statistical analyses
Categorical variables are expressed as proportions, and contin-
uous variables are presented as mean ± standard deviation or 
median (range) depending on the distribution of values. Demo-
graphics and quantitative PET data were compared between 
adenocarcinoma and squamous cell carcinoma patients using 
the Mann–Whitney U test or χ2 test. Intraclass correlation coef-
ficient (ICC) was calculated between each pair of lung tumor 
SUVmax value to agreement among the two readers. According 
3 of 9 birpublications.org/bjr Br J Radiol;92:20180792
BJRFull paper: BSREM and OSEM in different NSCLC subtypes
to Meyers et al, an ICC <0.69 was defined as poor, ICC between 
0.70 and 0.79 as fair, ICC between 0.80 and 0.89 as good and ICC 
>0.9 as high agreement.14 Further, we assessed the frequency 
of SUV-changes that were >30% or <30% comparing BSREM 
with OSEM, separately for adenocarcinoma and squamous cell 
carcinoma. The 30% cutoff was chosen corresponding to similar 
requirements for SUV change to address tumor response in other 
studies and guidelines.6 Analyses were carried out using SPSS 
release 23.0 (IBM Corporation, Armonk, NY) and MedCalc v. 
18.2 (MedCalc Software, Ostend, Belgium). A two-tailed p-value 
of <0.05 was considered to indicate statistical significance.
resulTs
A total of 58 patients (23 female, 35 male; median age 67, range 
46–83 years) referred for initial staging with 18F-FDG PET/
CT were included in this study. The patients had histologically 
confirmed adenocarcinoma (n = 34) and squamous cell carci-
noma (n = 24). Further demographic information on study 
patients is given in Table 1.
SUVmax in adenocarcinoma and squamous cell 
carcinoma
ICC indicated high agreement of lung tumor SUVmax measure-
ments among the two readers with 0.951 [p < 0.001, 95% confi-
dence interval (CI) 0.919–0.971]. A total of four (7%) cases with 
discrepancy of SUV measurements were resolved in consensus. 
The results of the quantitative assessment including all study 
patients are given in Table 2 and Figure 1. SUVmax was signifi-
cantly lower in adenocarcinomas compared to squamous cell 
carcinomas in OSEMTOF and OSEMPSF as well as in all BSREM 
reconstructions (all p < 0.01). BSREM350 resulted in the highest 
SUVmax for primary lung tumors with an average of 12.0 ± 5.0 
in adenocarcinoma and 18.1 ± 9.3 in squamous cell carcinoma, 
whereas we observed the lowest SUVmax in OSEMTOF with a 
SUVmax of 9.2 ± 4.0 in adenocarcinoma and 14.5 ± 7.0 in squa-
mous cell carcinoma, respectively.
Absolute and relative differences of PET values in 
different NSCLC histology
Table 3 demonstrates absolute and relative SUVmax differences of 
primary lung tumors among OSEM and BSREM reconstructions 
in adenocarcinoma and squamous cell carcinoma. Comparing 
BSREM to OSEMTOF, absolute SUVmax differences were highest 
in lower BSREM levels of 350 in adenocarcinoma with +2.9 ± 
1.6 and in squamous cell carcinoma with +4.0 ± 2.9, respectively. 
Absolute differences of SUVmax in reconstruction were similar 
in adenocarcinoma and squamous cell carcinoma (all p-values 
> 0.05).
We observed a statistically significant difference of the relative 
increase of SUVmax in adenocarcinoma compared to squamous 
cell carcinoma in BSREM350 compared to OSEMTOF, BSREM350 
compared to OSEMPSF, and BSREM450 compared to OSEMPSF, 
respectively (Table 3).
Image noise (i.e., SUVSD) in the bloodpool and the liver using 
OSEM and BSREM reconstructions were similar comparing PET 
scans of patients with adenocarcinoma and squamous cell carci-
noma (all p-values > 0.05), see Table 3.
Representative images of study subjects undergoing 18F-FDG 
PET/CT for lung cancer staging are given in Figure 2.
Impact of reconstruction methods on clinical tumor 
response assessment
We observed a significantly higher frequency of tumors that 
showed an increase of SUVmax >30% with BSREM compared 
to OSEMTOF in patients with adenocarcinoma (up to 56% of 
patients) compared to patients with squamous cell carcinoma 
(up to 29% of patients)(Figure  3). This was also observed, but 
less pronounced, when comparing BSREM with OSEMPSF (see 
Figure 3).
DIscussIon
This study sought to investigate if the impact of different recon-
struction algorithms (OSEM and BSREM) on absolute and 
relative SUV using digital PET/CT in lung cancer patients is clin-
ically relevant. The major findings of our study are as follows: (1) 
the absolute increase of SUVmax when applying BSREM instead 
of OSEM is not significantly different among adenocarcinoma 
and squamous cell carcinoma, (2) the mean relative increase 
of SUVmax comparing BSREM350 with OSEMTOF is +34.8% in 
adenocarcinoma and 23.4% in squamous cell carcinoma, (3) the 
relative increase of SUV comparing BSREM with OSEM may be 
significantly different among different histological subtypes of 
NSCLC, and (4) compared with OSEM the use of BSREM may 
increase the SUVmax of lung tumor by >30% in up to 56% of cases 
in adenocarcinoma and 25% of squamous cell carcinoma.
There is an increasing interest in quantitative 18F-FDG PET/CT 
as a tool for diagnosis, estimation of prognosis, and response 
monitoring in oncological diseases. If absolute quantification of 
metabolism by PET is achieved and results in consistent numer-
ical values of such, between different scanners and institutes that 
acquire the scans this would further enhance the role of this 
modality as an invaluable tool, particularly for therapy response 
assessment. However, PET/CT quantification using, SUV may be 
affected by different physiological and several technical factors,9 
including different reconstruction methods.11,12 As a conse-
quence, some of the variations in the literature on SUV-based 
patient outcomes may be explained by differences in 18F-FDG 
PET/CT study methods. With regard to NSCLC, former analysis 
suggested differences in the expression of proteins for glucose 
metabolism (e.g. GLUT1-transporter) between its two most 
frequent histological subtypes; adenocarcinoma and squamous 
cell carcinoma.15 This may explain the fact that there are vari-
ations of 18F-FDG uptake in different tumor histology with 
adenocarcinomas generally showing lower 18F-FDG uptake 
compared to squamous cell carcinomas.16,17 Indeed, also in our 
study group we observed significantly different SUVmax among 
different NSCLC histological subtypes, regardless of the recon-
struction method used, e.g. with a higher average SUVmax of 14.5 
(range 2.9–36.2) in squamous cell carcinomas as compared to 9.2 
(range 2.3–17.1) in adenocarcinoma using OSEMTOF.
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In recent years, OSEM reconstructions have been widely used 
instead of the initially used filtered back projection because of 
their overall improvement of image quality.18,19 OSEM methods 
thereby repeatedly iterate different possibilities of the raw data 
to find the most likely image and with each iteration step an 
image with a greater likelihood of describing the measured data 
is achieved. The main disadvantage of OSEM, however, is that it 
is not possible to run it to full convergence as the noise of PET 
images increases with each iteration step, leading to somewhat 
unacceptable images before full convergence is reached.11,20 
Therefore, OSEM is stopped after a predefined number of iter-
ations, resulting in underconverged images. As stated before, 
this leads to an underestimation of PET values, such as SUV. 
In contrast, novel BPL methods incorporate a penalty function 
(i.e. the β-value) as the only user-input variable which allows 
to choose the level of noise suppression applied and enables 




n = 24 p-valuea
Female/male, n (%) 18 (53%)/16 (47%) 5 (21%)/19 (79%) 0.015
Age, years, median (range) 66 (46–82) 70 (51–83) 0.076
Body weight, kg 71 ± 21 (39–124) 73 ± 14 (46–114) 0.421
Body height, m 1.70 ± 0.1 (1.49–1.87) 1.73 ± 0.1 (1.59–1.86) 0.343
BMI, kg/m2 24.3 ± 5.5 (15.0–38.7) 24.4 ± 4.2 (16.9–36.8) 0.608
Blood glucose level, mg/dl 100 ± 15 (72–157) 104 ± 20 (79–169) 0.434
Injected tracer activity, MBq 176 ± 79 (85–318) 180 ± 69 (91–295) 0.636
Scan time post-injection, min 60 ± 6 (50–76) 64 ± 11 (54–97) 0.141
PET/CT performed 0.898
  After histology 26 (76%) 18 (75%)
  Before histology 8 (24%) 6 (25%)
Time period scan after biopsy, d 16 ± 16 (1–57) 16 ± 12 (1–46) 0.452
Time period scan before biopsy, d 11 ± 6 (2–22) 31 ± 41 (2–104) 0.897
Maximal tumor diameter on CT, cm 4.3 ± 1.9 (1.7–8.4) 5.1 ± 2.2 (1.5–9.5) 0.155
T-classification 0.236
  T1 9 (26%) 3 (13%)
  T2 9 (26%) 11 (46%)
  T3 7 (21%) 3 (13%)
  T4 9 (26%) 7 (29%)
N-classification 0.056
  N0 11 (32%) 8 (33%)
  N1 6 (18%) 5 (21%)
  N2 7 (21%) 5 (21%)
  N3 10 (29%) 6 (25%)
M-classification 0.386
  M0 14 (41%) 20 (83%)
  M1 20 (59%) 4 (17%)
UICC stage, n (%) 0.408
  I 4 (12%) 3 (13%)
  II 3 (9%) 7 (29%)
  III 7 (21%) 10 (42%)
  IV 20 (59%) 4 (17%)
CT = computed tomography; MBq = Mega Becquerel; PET = Positron emission tomography; BMI, body mass index.
Values are given as absolute numbers and percentages in parenthesis or mean ± standard deviation (range) if not stated otherwise.
a
χ






































































Table 2. SUVmax of the primary lung tumor in different reconstruction settings as well as standard deviation of the standardized uptake value (SUVSD) as a measure for 
image noise
OSEM BSREM
OSEMTOF OSEMPSF BSREM350 BSREM450 BSREM600 BSREM800 BSREM1200
Adenocarcinoma, n = 34 SUVmax
Mean 9.2 9.8 12.0 11.5 11.0 10.5 10.0
Median 9.2 9.8 11.8 11.4 11.8 10.4 9.9
Range 2.3–17.1 2.3–18.7 2.6–24.4 2.5–23.8 2.5–22.9 2.4–21.9 2.3–20.2
Squamous cell carcinoma, n = 24 SUVmax
Mean 14.5 15.5 18.1 17.5 17.0 16.4 15.6
Median 14.0 14.6 16.9 16.3 15.6 15.1 14.7
Range 2.9–36.2 3.2–39.3 3.7–49.7 3.6–48.0 3.4–46.0 3.2–43.8 2.9–40.5
p-valuea 0.001 0.001 0.005 0.004 0.003 0.002 0.001
Adenocarcinoma, n = 34 Image noiseb
Mediastinum 0.15 ± 0.05 0.13 ± 0.05 0.18 ± 0.05 0.14 ± 0.04 0.12 ± 0.03 0.10 ± 0.02 0.08 ± 0.02
Liver 0.28 ± 0.07 0.25 ± 0.06 0.30 ± 0.06 0.26 ± 0.05 0.22 ± 0.04 0.19 ± 0.04 0.15 ± 0.03
Squamous cell carcinoma, n = 24 Image noiseb
Mediastinum 0.16 ± 0.07 0.14 ± 0.06 0.19 ± 0.09 0.16 ± 0.08 0.13 ± 0.06 0.11 ± 0.05 0.09 ± 0.04
Liver 0.28 ± 0.07 0.26 ± 0.07 0.29 ± 0.07 0.26 ± 0.06 0.22 ± 0.06 0.19 ± 0.05 0.16 ± 0.04
p-valuea Mediastinum 0.752 0.856 0.807 0.812 0.733 0.962 0.589
p-valuea Liver 0.899 0.931 0.472 0.602 0.862 0.681 0.937
BSREM, block sequential regularized expectation maximization; OSEM, ordered subset expectation maximization; PSF, point spread function modelling; SUVmax, maximum standardized uptake 
value; TOF, time of flight.
p-values for comparison of SUVs in adenocarcinomas and squamous cell carcinomas are given at the bottom of the table.
aMann–Whitney U test
bSUVSD; measured in a 1.0 cm spherical VOI in the descending aorta and a 4.0 cm spherical VOI in the right lobe of the liver
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to increase the number of iterations without excessive image 
noise.21 BSREM is an algorithm that is used to solve this penal-
ized likelihood objective function. Thereby, it can use more 
iterations without recovering high frequency components from 
noise. Hence, it can get very close to convergence at the voxel 
level and it was already previously described that BPL-based 
reconstruction may increase the accuracy of lesion quantitation 
compared to OSEM, with a particular improvement in quantifi-
cation in cold background regions such as the lungs.22
An attempt to explain the principal finding of why relative SUV 
changes in digital PET/CT using BSREM instead of OSEM are 
significantly different among different NSCLC histologies may 
be as follows: given the usually lower SUV of adenocarcinomas, 
as aforementioned, they are more underconverged using OSEM 
reconstruction compared to squamous cell carcinoma. This can 
be attributed to the fact that one has a higher activity concen-
tration to the other on average, hence it is known that focal 
uptake with higher activity concentration tend to converge faster 
and uptake with lower activity concentration tend to converge 
slower. So the convergence benefit of BSREM reconstruction 
in providing more convergent foci compared to OSEM is more 
felt with adenocarcinoma as they are more underconverged and 
have a differential improvement to squamous cell carcinoma. 
Figure 1. Box plots of absolute SUVmax for all primary lung 
tumors for OSEM and BSREM reconstruction, for patients with 
adenocarcinoma (n = 34) and squamous cell carcinoma (n = 
24). Box and whisker plots show IQR from the 25 to 75% per-
centile and the upper fence of the 1.5 IQR above the 75% per-
centile or lower fence of the 1.5 IQR below the 25% percentile. 
* p < 0.01; ** p = 0.001; for SUVmax in squamous cell carcinoma 
compared to adenocarcinoma. BSREM, block sequential reg-
ularized expectation maximization; OSEM, ordered subsetex-
pectation maximization; IQR, interquartile range.
Table 3. Absolute and relative SUVmax differences among OSEM and BSREM reconstructions of lung cancers
Adenocarcinoma, n = 34 Squamous cell carcinoma, n = 24 p-valuea
Absolute ΔSUVmax BSREM350 to OSEMTOF +2.9±1.6 +4.0±2.9 0.403
BSREM450 to OSEMTOF +2.4±1.5 +3.4±2.5 0.324
BSREM600 to OSEMTOF +1.9±1.4 +2.8±2.1 0.132
BSREM800 to OSEMTOF +1.4±1.3 +2.1±1.6 0.029
BSREM1200 to OSEMTOF +0.8±1.0 +1.2±1.0 0.077
Relative ΔSUVmax BSREM350 to OSEMTOF +34.8±20.5% +23.4%±7.7 0.048
BSREM450 to OSEMTOF +28.8±18.4% +19.7%±6.2 0.072
BSREM600 to OSEMTOF +22.6±16.7% +16.2%±5.1 0.276
BSREM800 to OSEMTOF +16.2±14.9% +12.6%±4.2 0.728
BSREM1200 to OSEMTOF +9.7±11.7% +7.3%±3.4 0.528
Absolute ΔSUVmax BSREM350 to OSEMPSF +2.2±1.2 +2.9±2.3 0.788
BSREM450 to OSEMPSF +1.7±1.1 +2.2±1.9 0.597
BSREM600 to OSEMPSF +1.2±1.0 +1.7±1.5 0.269
BSREM800 to OSEMPSF +0.7±0.8 +1.0±1.0 0.136
BSREM1200 to OSEMPSF +0.1±0.7 +0.1±0.5 0.868
Relative ΔSUVmax BSREM350 to OSEMPSF +24.4±13.8% +15.6%±5.6 0.012
BSREM450 to OSEMPSF +18.9±11.7% +12.1%±4.1 0.021
BSREM600 to OSEMPSF +13.2±10.1% +8.8%±3.3 0.172
BSREM800 to OSEMPSF +7.3±8.7% +5.4%±2.7 0.850
BSREM1200 to OSEMPSF +1.4±6.7% +0.5%±2.7 0.425
BSREM, block sequential regularized expectation maximization; OSEM, ordered subset expectation maximization; PSF, point spread function 
modelling; SUVmax, maximum standardized uptake value; TOF, time of flight.
Values are given as mean ± standard deviation.
aMann–Whitney U test
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We could argue that the changes we see with BSREM are due 
to histology differences but also due to the underconvergence 
difference produced by OSEM which is again less for squa-
mous cell carcinoma. Therefore, the benefit of convergence with 
BSREM is more pronounced with adenocarcinoma. This also 
leads to the fact that differences with BSREM are more indica-
tive of real histology difference than differences occurring from 
differential convergence of OSEM. One might also extrapolate 
this to other subtypes of cancers since this effect is reconstruc-
tion-related. Future studies may have to elucidate absolute and 
relative impact of BSREM compared to OSEM as well.
Overall, this fact needs to be taken into account if SUV are used as 
a basis for treatment strategy decisions or outcome comparisons 
across different centers. We even observed a substantial number 
of patients (up to 56%) that had an increase of lung tumor 
SUVmax by >30% simply by using BSREM instead of OSEM. This 
was more often observed in adenocarcinomas than in squamous 
cell carcinomas. Notably, such increases were particularly seen 
with lower β-values (19/34 adenocarcinomas with BSREM350, 
13/34 with BSREM450). In another study, such low β-values were 
shown to yield the optimum image quality for lung cancer,23 and 
are hence expected to be utilized more frequently in the staging 
of lung cancer patients compared to reconstruction settings with 
higher β-values. A recent study by Furumoto et al investigated 
the predictive value of PET/CT in clinical stage IA adenocarci-
nomas of the lung in terms of clinical outcome and patholog-
ical invasiveness.24 Notably, Furumoto et al found that aside the 
volume of the solid part of the pulmonary lesion, the SUVmax 
(cutoff value of 2.4 using OSEM) was highly beneficial for the 
prediction of survival and pathological invasiveness. This study 
is exemplary for the raising prognostic importance of 18F-FDG 
PET/CT. Relating their results to the results of our study, we 
assume that these cutoff values would need to be adapted when 
using BSREM instead of OSEM. Further studies may elucidate 
SUV adaptions needed for different tumor entities, tumor histol-
ogies and clinical scenarios when applying BSREM.
There are some limitations of our study that have to be consid-
ered. First, the included number of patients is relatively small 
and only from a single center, therefore further studies, ideally 
in a multicenter setting, are needed to confirm our findings. 
Second, analyses of tumor SUV were restricted to measurement 
of SUVmax, which remains the main parameter used in clinical 
care. Future evaluations of corrected SUV-values may lead to 
different results for different reconstruction methods. Third, 
given that more patients with NSCLC referred to our department 
for imaging are diagnosed with adenocarcinoma as compared to 
Figure 2. Representative images of patients that underwent 
18F-FDG PET/CT for lung cancer staging. Axial PET/CT images 
(A, B) show FDG-avid intrapulmonary lesions. Histopathology 
confirmed an adenocarcinoma in (A) and squamous cell car-
cinoma in (B). Corresponding SUVmax are presented (C and 
D) for OSEMTOF, OSEMPSF, BSREM350, BSREM450, BSREM600, 
BSREM800, and BSREM1200. While the absolute increase of 
SUVmax using BSREM compared to OSEM is similar in both 
cases, the relative increase is more pronounced in the patient 
with adenocarcinoma. 18F-FDG, 18F-fludeoxyglucose; BSREM, 
block sequential regularized expectation maximization; 
OSEM, ordered subset expectation maximization; SUVmax, 
maximum standardized uptake value.
Figure 3. Frequency of patients with an SUVmax increase by 
>30% when using BSREM instead of OSEM. We observed the 
tumor SUVmax to increase by >30% most often in patients with 
adenocarcinoma, when using BSREM with lower β-values, and 
when comparing BSREM with OSEMTOF (A). This was less fre-
quent when comparing BSREM with OSEMPSF (B).
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squamous cell carcinoma we were not able to include a 1:1 ratio 
of this two histological subtypes which may be desired in future 
evaluations.
conclusIons
BSREM leads to a significant increase of SUV in both adenocar-
cinoma and squamous cell carcinoma compared to OSEM. The 
relative change of SUVmax comparing BSREM with OSEM may 
be significantly different among different histological subtypes 
of NSCLC and is more pronounced in adenocarcinomas. This 
highlights the importance for careful standardisation of β-value 
used for serial 18F-FDG PET scans when following-up NSCLC 
patients.
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